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Abstract
Bone is constantly being remodelled in a dynamic
process where osteoblasts are responsible for bone
formation and osteoclasts for its resorption.
Osteoblasts are specialized mesenchymal cells
that undergo a process of maturation where genes
like core-binding factor α1 (Cbfa1) and osterix (Osx)
play a very important role. Moreover, it was found
recently that the Wnt/β-catenin pathway plays a
part on osteoblast differentiation and proliferation.
In fact, mutations on some of the proteins involved
in this pathway, like the low-density lipoprotein re-
ceptor related protein 5/6 (LRP5/6), lead to bone di-
seases.
Osteoblasts have also a role in the regulation of
bone resorption through receptor activator of nu-
clear factor-κB (RANK) ligand (RANKL), that links
to its receptor, RANK, on the surface of pre-osteo-
clast cells, inducing their differentiation and fu-
sion. On the other hand, osteoblasts secrete a so-
luble decoy receptor (osteoprotegerin, OPG) that
blocks RANK/RANKL interaction by binding to
RANKL and, thus, prevents osteoclast differentia-
tion and activation. Therefore, the balance betwe-
en RANKL and OPG determines the formation and
activity of osteoclasts. 
Another factor that influences bone mass is lep-
tin, a hormone produced by adipocytes that have
a dual effect. It can act through the central nervous
system and diminish osteoblasts activity, or can
have an osteogenic effect by binding directly to its
receptors on the surface of osteoblast cells.
Keywords: Osteoblasts; Bone Formation; Wnt/β-
-catenin Signalling; Leptin; Cbfa1.
Resumo
O osso está em constante remodelação num pro-
cesso dinâmico, em que os osteoblastos são res-
ponsáveis pela sua formação e os osteoclastos pela
sua reabsorção. 
Os osteoblastos derivam de células mesen-
quimatosas que sofreram um processo de ma-
turação, no qual genes como o core-binding factor
α1 (Cbfa1) e osterix (Osx) assumem um papel de
grande importância. Foi descoberto recentemente
que a via de sinalização Wnt/β-catenina tem um
papel relevante na diferenciação e proliferação do
osteoblasto. Na realidade, mutações em deter-
minadas proteínas envolvidas nesta via, como 
o co-receptor low-density lipoprotein receptor re-
lated protein 5/6 (LRP5/6), são causa de doenças
ósseas. 
Os osteoblastos desempenham também um pa-
pel importante na regulação da reabsorção óssea
através do receptor activator of nuclear factor-κB
(RANK) ligand (RANKL) que interage com o seu re-
ceptor RANK, expresso na superfície de pré-osteo-
clastos, induzindo a diferenciação e fusão destas
células. Por outro lado, os osteoblastos secretam
um receptor solúvel, a osteoprotegerina (OPG), que
bloqueia a interacção RANK/RANKL através da sua
ligação ao RANKL, prevenindo assim a diferencia-
ção e activação do osteoclasto. Desta forma, o ba-
lanço entre RANKL e OPG determina a formação e
actividade do osteoclasto.
Outro factor que influencia a massa ós-
sea é a leptina, uma hormona produzida pelos
adipócitos, que tem um efeito duplo. Pode actuar
através do sistema nervoso central e diminuir a 
actividade do osteoblasto, ou pode exercer um
efeito osteogénico através da interacção com os 
receptores presentes na superfície do osteo-
blasto.
Palavras-chave: Osteoblastos; Formação do Osso;
Sinalização Wnt/β-catenina; Leptina; Cbfa1.
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Introduction
Bone must be stiff, slightly flexible and light in or-
der to make loading possible and facilitate move-
ment. In particular, bone has a specific characteris-
tic that distinguishes it from other materials: this
tissue can respond according to the location and
extent of the damage, remove it and replace it with
new bone.1
Bone is composed by cells and an extracellular
matrix which becomes mineralized by the depo-
sition of calcium hydroxyapatite, giving the bone
rigidity and strength. Bone has three distinct cell
types: the osteoblasts, or bone-forming cells, the
osteoclasts, or bone-resorbing cells, whose functi-
ons are intimately linked,2 and the osteocytes,
which are osteoblasts entrapped within lacunae.
In order to balance bone formation and resorption
in healthy individuals, osteoblasts secrete factors
that regulate the differentiation of osteoclasts and
osteocytes secrete factors regulating the activity of
both osteoblasts3 and osteoclasts.1 Bone is cons-
tantly being resorbed by osteoclasts and then re-
placed by osteoblasts in a process called bone re-
modelling.2 Resorption is much faster than forma-
tion: an area of bone can be resorbed in 2-3 weeks
but it takes at least three months to rebuild it.4 Bone
resorption is probably  the first event that occurs
in response to a mechanical stress signal.5 In fact,
resorption and formation are tightly coupled, so
that after resorption a formation phase occurs and,
normally, the amount of bone resorbed will be for-
med in the succeeding phase (Figure 1). This coor-
dination arises from the linkage between osteo-
blasts and osteoclasts, which is mediated by the
release of growth factors from bone during re-
sorption.6
On the other hand, osteoblasts, have, in addition
to their classic role as bone forming cells, the abili-
ty to regulate bone resorption through the expres-
sion of receptor activator of nuclear factor-κB
(RANK) ligand (RANKL), which links to its recep-
tor, RANK, on the surface of pre-osteoclast cells, in-
ducing their differentiation and causing bone
resorption. On the contrary, the soluble decoy re-
ceptor (osteoprotegerin, OPG), also produced by
osteoblasts, is able to block RANK/RANKL interac-
tion by binding to RANKL and, thus, prevent osteo-
clast differentiation and activation, reducing bone
resorption.6
In this article, we will review osteoblast biology
and the processes that influence bone formation
and resorption through this cell.
Osteoblasts
Osteoblasts have a very important role in creating
and maintaining skeletal architecture; these cells
are responsible for the deposition of bone matrix
and for osteoclasts regulation. Osteoblasts are mo-
nonuclear, not terminally differentiated, speciali-
zed cells.7 When they are active, a large Golgi ap-
paratus and an abundant rough endoplasmic reti-
culum is visible. In addition, osteoblasts form tight
junctions with adjacent osteoblasts and have re-
gions of the plasma membrane specialized in ve-
sicular trafficking and secretion.8 As they differen-
tiate they acquire the ability to secrete bone ma-
trix.6 Ultimately, some osteoblasts become trapped
in their own bone matrix giving rise to osteocytes
which, gradually, stop secreting osteoid.8 Osteo-
cytes are the most abundant cells in bone; these
cells communicate with each other and with the
surrounding medium through extensions of their
plasma membrane.9,10 Therefore, osteocytes are
thought to act as mechanosensors, instructing os-
teoclasts where and when to resorb bone and os-
teoblasts where and when to form it.1,10
Figure 1. Bone is constantly being resorbed by osteoclasts
and formed by osteoblasts in a coupled process, mediated
by the release of growth factors from bone during 
resorption and by molecules produced by osteoblasts,
which regulate the differentiation of osteoclasts.
(Osteoblasts and osteoclasts symbols were adapted from
Rheugulation Database, knowledge base on rheumatoid
arthritis, www.rheugulationdb.com)
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Wnt pathway on osteoblastogenesis
Wnts are secreted glycoproteins that are found in
all animal species.11 The human genome encodes
19 Wnt genes that bind to cell-surface receptors
and mediate a cascade of events that regulate a va-
riety of cellular activities, including cell fate, deter-
mination, proliferation, migration, polarity and
gene expression. Wnts activate three distinct in-
tracellular signalling cascades: the Wnt/β-catenin
pathway, the Wnt/Ca2+ pathway and the Wnt/pla-
nar polarity pathway. The Wnt/β-catenin pathway
is frequently referred to as the canonical pathway
and it promotes cell fate determination, prolifera-
tion and survival through the increase of β-catenin
levels and alteration of gene expression by the
transcription factor Lymphoid enhancer factor/T
cell factor (Lef/Tcf).12 Activation of this signalling
pathway occurs with binding of Wnt to Frizzled
(Fz), a transmembrane receptor, and low-density
lipoprotein receptor related protein 5/6 (LRP5/6)
co-receptors11, 13 (Figure 2). In the absence of a Wnt
ligand, the cytosolic level of β-catenin is kept low
by its phosphorylation and degradation, thereby
suppressing the expression of Wnt-responsive ge-
nes.12 Inappropriate activation of Wnt signalling
contributes to cancer and reduced Wnt signalling
has been associated with osteoporosis.11,14
The first indication that Wnt signalling has an
important role in bone formation came from stu-
dies in humans where mutations that inactivate
the Wnt co-receptor LRP5 were shown to cause os-
teoporosis. Moreover, gain-of-function mutations
in this receptor increased Wnt signalling and resul-
ted in a high bone mass phenotype, both in hu-
mans and mice,15 due to an elevated number of ac-
tive osteoblasts which seem to be protected from
apoptosis. In fact, the mutation G171V on LRP5 is
a missense mutation14 that decreases the interac-
tion between LRP5 and the Wnt antagonist Dick-
kopf1 (Dkk1), thereby diminishing its inhibitory
effect on endogenous Wnt signalling.3 In mice, null
mutations in LRP5 resulted in bone loss after birth,
due to decrease in bone formation and osteoblast
proliferation.4 Therefore, loss-of-function mu-
tations in LRP5 lead to low bone density whereas
gain-of-function mutations cause high bone
mass.14 It was also found that a series of genes in-
volved in the Wnt signalling pathway are induced
during fracture repair in rodents, giving strength to
the relation between Wnt signalling and LRP5 on
bone.4
LRP5 is expressed at low levels in various tis-
sues, shows little temporal changes, and constitu-
tes a key factor in bone regulation. This effect is
linked to the role of LRP5 on the Wnt signalling
pathway. LRP5 interacts with proteins from the
Wnt family to form a complex with Fz, leading to
the activation of the canonical Wnt signalling path-
way.4 In fact, β-catenin activity is essential for the
differentiation of mature osteoblasts and, conse-
quently, for bone formation. However, lack of this
molecule does not change the differentiation of
osteoprogenitor cells into the early osteoblastic
precursors but, instead, it blocks the expression of
Osterix (Osx) and, as a consequence, these cells ac-
quire a chondrogenic phenotype.3 The effect of
LRP5 on bone mass is mediated by the β-catenin
Wnt signalling pathway and, in vitro, it results in
Figure 2. Canonical Wnt signalling has multiple roles in
osteoblastogenesis, is essential for osteoblast lineage 
differentiation early in the development and, postnatally, is 
involved in osteoblast proliferation, survival and lifespan.
Binding of Wnt to Frizzled and LRP5/6 receptors induce a
signalling cascade that allows the accumulation of 
β-catenin in the citosol. β-catenin then enters the nucleus
where it promotes the transcription of target genes.
APC – Adenomatous Polyposis Coli; Dkk – Dickkopf;
Dsh – Dishvelled protein; Fz – Frizzled receptor;
GSK3 – Glycogen Synthase Kinase-3β; LRP5/6 – Low-
-density Lipoprotein Receptor Related Protein 5/6;
sFRP – secreted frizzled-related protein;WIF-1 – Wnt 
inhibitory factor; Lef/Tcf – lymphoid enhancer factor/T
cell factor. (Adapted from Krishnan et al.)13
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the expression of an early osteoblast marker, alka-
line phosphatase (ALP). Although this signalling
pathway is involved in the regulation of osteoblas-
togenesis and bone formation, a specific Wnt pro-
tein that triggers its activation has still not been
identified.15 In fact, several Wnt genes, such as
Wnt1, Wnt4, Wnt5α, Wnt9α/14 and Wnt7b are ex-
pressed in either osteoblast precursors or adjacent
tissues during development, and Wnt3α and
Wnt10b are expressed in bone marrow,13 but only
Wnt10b mutants express a postnatal decrease in
bone mass.3 The expression of Wnt10b in mesen-
chymal progenitor cells, in vitro, induces the ex-
pression of the transcription factors core binding
factor α1 (Cbfa1), Distal-less homeobox 5 (Dlx5)
and Osx, stimulating osteoblastogenesis. These
observations substantiate the fact that Wnt signal-
ling influences the differentiation of the precursor
cells by increasing the expression of key osteoblas-
togenic transcription factors15 (Figure 3). On the
other hand, Wnt10b inhibits the transcription fac-
tors CCAAT/enhancer-binding protein α (C/EBPα)
and peroxisome proliferator-activated receptor γ
(PPARγ),  blocking adipogenesis.15 Thus, Wnts have
also a role on mesenchymal precursor cells linea-
ge commitment and adipogenesis is most likely
the default pathway for the cells that do not recei-
ve proper inductive signals to become osteoblasts,
chondrocytes, myocytes or other mesodermal
cells.12 As a matter of fact, a relationship between
osteoblast and adipocyte differentiation might ex-
ist, where an increase in osteoblast differentiation
is associated with a decrease in adipocyte differen-
tiation. 
Wnt signalling is tightly regulated by secreted
antagonists. An example of this regulation is the in-
teraction of Wnt with the receptor Fz which is in-
hibited by members of the secreted frizzled-rela-
ted protein family (sFRP) and Wnt inhibitory fac-
tor (WIF-1).12 On the other hand, LRP5/6 activity is
antagonized by sclerostin (encoded by the SOST
gene) and members of the Dkk family.13 Canonical
Wnts upregulate Dkk2 expression which, in turn,
controls some of the processes required for termi-
nal osteoblast differentiation, mostly by removing
the cells from the cell cycle. In fact, Dkk2 is impor-
tant in late stages of osteogenic differentiation,
particularly for the formation of mineralized ma-
trix.16 LRP5 and LRP6 are receptors for the Wnts
and for other types of molecules such as scleros-
tin, which is produced by osteocytes, inhibiting the
proliferation and maturation of osteoblasts and
promoting their apoptosis. Mutations that reduce
SOST function, in humans, cause abnormal growth
of bone tissue, giving rise to a disease named scle-
rosteosis. Also, the function of mature osteoblasts,
including the ability to synthesize extracelular ma-
trix proteins requires LRP5 as well as the signalling
protein activating-transcription factor 4 (ATF4).5
Wnt/β-catenin pathway acts by attenuating os-
teoclastogenesis13 through transcriptional regula-
tion of OPG, since the expression of this molecule
was found to be upregulated by canonical Wnt sig-
nalling in an in vitro screen for Wnt-regulated ge-
nes. OPG is also a direct target of the β-catenin-Tcf
complex in osteoblasts, and Tcf1 is probably a
transcription factor required for OPG regulation.3
Genes expressed in osteoblasts
Osteoblasts derive from mesenchymal precursor
cells8,17 which also originate chondrocytes, myo-
blasts, adipocytes and tendon cells, depending on
the transcription factors that regulate the path-
way.4,5,18 Three of these transcription factors are
Cbfa1, Osx and ATF4, which have been identified
as controllers of the osteoblastic lineage.5,18 In the
absence of Cbfa1 and Osx, no osteoblasts are for-
med. Also, bone morphogenic proteins (BMPs),
Figure 3. Mesenchymal precursor cells give rise to 
several cell types, among which are osteoblasts.
ALP – alkaline phosphatase; ATF4 – activating 
transcription factor 4; cbfa1 – core binding factor α1;
COL1 – collagen type Iα1; C/EBPα - CCAAT/
/enhancer-binding protein α; Dlx5 – distal-less homeobox
5; LRP5/6 – low – density lipoprotein receptor related 
protein 5/6; Osx – osterix; OPN – osteopontin;
PPARγ – peroxisome proliferators-activated receptor γ;
RANKL – receptor activator of nuclear factor-κB ligand.
(Osteoblasts and osteoclasts symbols were adapted from
Rheugulation Database, knowledge base on rheumatoid
arthritis, www.rheugulationdb.com)
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members of a family of secreted growth factors,
provide important and specific signals that are es-
sential for full osteoblastogenic differentiation.5 In
cell culture, osteoblasts resemble fibroblasts; the
only morphological trait osteoblast specific is lo-
cated outside the cell in the form of a mineralized
extracelular matrix. Moreover, all the genes expres-
sed in fibroblasts are also expressed in osteoblasts.
In fact, these cells have only two specific trans-
cripts, one encoding Cbfa1 and other encoding os-
teocalcin, an inhibitor of osteoclast function that
is only expressed when these cells are completely
differentiated.2
Cbfa1, also known as Runx2, Osf2 and AML3,4
has all the properties of a differentiation factor for
the osteoblast lineage. During embryonic develop-
ment, Cbfa1 is expressed just before osteoblast dif-
ferentiation and only in mesenchymal cells com-
mitted to become either chondrocytes or osteo-
blasts. Subsequently, the expression of this trans-
cription factor becomes limited to osteoblasts2 and
is required for the expression of osteoblast-speci-
fic proteins, such as osteocalcin.8 Cbfa1-null mice
lack osteoblasts. However, they are able to develop
cartilage with late chondrocyte maturation.2,4 Also,
through regulation of osteocalcin expression,
Cbfa1 controls bone formation by differentiated
osteoblasts. Binding sites for Cbfa1 are also present
in the regulatory sequences of most genes that are
required for the synthesis of extracelular matrix.2
Osx is another factor involved on osteoblast diffe-
rentiation and acts downstream of Cbfa1 to indu-
ce differentiation of osteoblasts. Mice that are de-
ficient in Osx develop a normal-shape skeleton
composed only by cartilage, without osteoblasts
or mineralized matrix. However, their cartilage is
normal, containing fully differentiated chon-
drocytes, which points to a specific role of Osx in
osteoblast differentiation.4
During differentiation, osteoblasts express a
characteristic pattern of genes that distinguish
them from other cell types. Collagen type Iα1
(COL1) is expressed from the beginning of osteo-
blast differentiation and is the main structural
component of bone matrix. Osteopontin (OPN), a
non-collagenous matrix protein, and ALP are im-
portant in stabilizing the matrix. Osteocalcin is
another non-collagenous protein that is almost ex-
clusively expressed in bone and is up-regulated in
the late differentiation stage. This stage coincides
with the onset of mineralization suggesting that
osteocalcin may play a part in the regulation of
matrix mineralization.19
RANKL and OPG 
RANKL is a member of the Tumour Necrosis Fac-
tor (TNF) superfamily of cytokines. Also known as
TNFSF11, TRANCE, OPGL, ODF and CD252,20
RANKL was initially identified as a cytokine produ-
ced by T cells and needed for their interaction with
dendritic cells21 and later it was found that this pro-
tein mediates the differentiation of T and B lym-
phocytes.22 RANKL is produced as a membrane-
bound protein in osteoblasts, bone marrow stro-
mal cells, activated T lymphocytes23 and smooth
muscle cells24 and cleaved into a soluble form by a
metalloprotease.23 The cell-bound form is the most
common and is expressed by many cell types. On
the other hand, the expression of the secreted form
is restricted to activated T cells25, 26 and mast cells.27
Structurally, RANKL has an organization very simi-
lar to that of other TNF family members, with a
short intracellular domain and a long extracelular
domain, where the first exons encode for the intra-
cellular domain, and the extracelular domain is
encoded by the middle and last exons. In fact,
through analysis of the phylogeny of the TNF fa-
mily, it was found that RANKL is closely related to
CD40L and that these molecules appear to derive
from an ancestor gene that diverged from other
TNF family members.20
TNF family members mediate several biological
processes and RANKL is specially important in
bone, in the immune system22 and in mammary
epithelium.28 In bone, the expression of RANKL on
osteoblast cells allow the maturation, differentia-
tion and activation of osteoclasts by binding to its
receptor, RANK (Figure 4), on osteoclast precur-
sors, in the presence of macrophage-colony sti-
mulating factor (M-CSF).29,30 Deletion of the RAN-
KL gene in mice resulted in severe osteopetrosis
and a complete lack of osteoclasts, as a result of an
inability of osteoblasts to support osteoclastogene-
sis.20 Analysis of RANKL promoter revealed the pre-
sence of binding sites for two potent stimulators of
this protein, vitamin D and glucocorticoids, as well
as the binding site for Cbfa1.26,30
OPG, also known as TNFRS11B, OCIF and TR1,
was first identified in 1997 as being a protein that
exhibits a protective effect on bone.31 Although, it
is expressed ubiquitously and abundantly in many
tissues and cell types.26 OPG is a member of the
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TNF receptor superfamily, which consists of trans-
membranar proteins that evoke signal transduc-
tion, mediating several biological responses, such
as cytotoxicity, apoptosis and cell survival, prolife-
ration and differentiation.31,32 OPG was identified
only as a soluble protein,31,33 closely related to
CD40,29 which is able to bind to its respective li-
gand, thereby preventing the activation of cellular
targets. In fact, the main function of OPG is to an-
tagonize RANKL effects, by interrupting the sig-
nalling between osteoblasts and osteoclast proge-
nitors28,34 (Figure 4). Indeed, over expression of OPG
in mice resulted in osteopetrosis, due to inhibiti-
on of osteoclast maturation, whereas OPG-defi-
cient mice exhibit osteoporosis.25
The human OPG gene is located on chromoso-
me 8, in an area closely linked to other proteins in-
volved in bone-forming activity, which raised the
possibility that this region may enclose a cluster of
genes involved in the regulation of bone develop-
ment and metabolism.31 The promoter region of
the OPG gene has also several polymorphisms that
could result in altered binding of transcription fac-
tors, possibly affecting gene transcription,35 and
result in changes in bone mineral density which,
ultimately, might lead to bone metabolic disea-
ses.34
RANKL and OPG are both produced by osteo-
blasts and have an important role in regulating os-
teoclasts.5,6 It has been proposed that several fac-
tors can regulate the RANKL/OPG ratio and, thus,
regulate osteoclastogenesis. Among these factors
are vitamin D3,31 IL-1α, IL-1β, TNFα, TNFβ, bone
morphogenic protein (BMP) 2, transforming growth
factor β (TGFβ) and 17β-estradiol that increase OPG
levels, whereas prostaglandin E2 (PGE2), parathyroid
hormone (PTH),29 glucocorticoids and insulin-like
growth factor-1 (IGF-1) decrease them.36 There is
also evidence pointing to a change of RANKL/OPG
ratio in response to gene transcription activity due
to polymorphisms enclosed in their promoter regi-
ons.35 On the other hand, PTH, PGE2, inflammatory
cytokines and vitamin D3 stimulate RANKL, whereas
the expression of this molecule is attenuated by es-
trogen and TGFβ.37
In an in vitro study, RANKL mRNA levels were
found to be higher in undifferentiated cells and
decrease 5-fold during osteoblasts differentiation,
whereas OPG mRNA levels were much lower in un-
differentiated cells and increased 7-fold during dif-
ferentiation. Moreover, these findings are in agree-
ment with the fact that only undifferentiated cells
can support osteoclastogenesis, while partially or
completely differentiated cells cannot.6 Accor-
dingly, the amount of RANKL and OPG expressed
by osteoblasts depends on their stage of differen-
tiation: pre-osteoblast cells express high levels of
RANKL and relatively low levels of OPG, thus sti-
mulating osteoclast differentiation and function.
On the other hand, more mature osteoblasts ex-
press higher levels of OPG, in comparison to RAN-
KL levels, inhibiting osteoclast differentiation and
function.5 Hence, a high RANKL/OPG ratio in bone
microenvironment is the main molecular mecha-
nism that determines osteoclastogenesis.6,23 RAN-
KL and OPG mRNA levels were shown to correlate
with altered resorption in response to physiologi-
cal stimuli, such as calcium concentration and hor-
monal treatment.19
The role of Leptin
Leptin was first identified as an hormone secreted
Figure 4. Osteoblasts secrete two proteins, RANKL and
OPG, which are responsible for the communication 
between osteoclasts and their precursors.These two
molecules have antagonistic effects on bone mass; while
RANKL induce bone resorption, OPG blocks it. Leptin
can act through the hypothalamus blocking osteoblast 
activity, or it can act directly on osteoblast receptors 
enhancing osteoblast function. IGF-1 – insulin-like growth
factor 1; M-CSF – macrophage-colony stimulating factor;
OB-R – leptin receptor; OPG – osteoprotegerin; PGE2 –
prostaglandin E2; PTH – parathyroid hormone; RANK –
receptor activator of nuclear factor-κB; RANKL - RANK
ligand;TGFβ – transforming growth factor β. (Osteoblasts
and osteoclasts symbols were adapted from Rheugulation
Database, knowledge base on rheumatoid arthritis,
www.rheugulationdb.com)
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by the white adipose tissue.23 It acts by binding to
a hypothalamus receptor and regulates body
weight through appetite suppression and increa-
sed energy expending.4 Leptin is known to act in
the immune system, reproduction, development,
hematopoiesis, angiogenesis and in the skeletal
tissue.38
Two opposing mechanisms have been sugges-
ted to explain the effect of leptin on bone metabo-
lism. On one hand, leptin can act locally to promo-
te the development of osteoprogenitor cells and
stimulate osteoblasts to form new bone and, on
the other hand, leptin can act through the central
nervous system decreasing osteoblast activity23 (Fi-
gure 4). Mice genetically deficient in leptin, or lep-
tin receptor, have an obese phenotype, with a high
bone mass.2,38 However, when leptin is injected in-
tracerebroventricularly, there is a decrease in bone-
forming activity and a return to the bone mass seen
in a wild-type mice, suggesting that leptin acts
through a central pathway after binding to its re-
ceptor in the hypothalamic nuclei.38,39 In addition,
increased serum levels of leptin decrease bone
mass suggesting that serum levels of this hormo-
ne might control bone mass through a neuronal
pathway.40 It is still unclear which are the mecha-
nisms relating leptin, central nervous system and
bone. However, it is known that in the hypothala-
mic nuclei leptin receptors are co expressed in neu-
rons expressing the appetite-suppressing neuro-
peptides proopiomelanocortin (POMC) and cocai-
ne-and amphetamine-regulated transcript (CART)
and in neurons expressing the appetite-inducing
neuropeptide Y (NPY) and agouti-related peptide
(AgRP). Interestingly, intracerebroventricular in-
jection of leptin results in reduced expression of
NPY and AgRP and increased expression of POMC.
Thus, this provides preliminary evidence that the
melanocortin pathway might be involved in leptin
signalling, at least for its appetite regulator role.41 
When leptin acts directly on osteoblast and
chondrocyte surface receptors it can have an os-
teogenic effect.38,39 There are six isoforms of the lep-
tin receptor (OB-R), created by different splicing
variants of the gene ob, but only four of them (OB-
-Ra, OB-Rb, OB-Rc and OB-Rf) are expressed on
osteoblasts. From these, just OB-Ra and OB-Rb are
able to mediate leptin-induced signalling trans-
duction into the cell.42 It was also found that pri-
mary human osteoblasts transcribe, translate and
secrete leptin and that leptin expression fluctuates
during its differentiation. In fact, in mesenchymal
cells, leptin expression is present and in prolifera-
ting osteoblasts is suppressed, while it reappears
in late stage osteoblasts. Accordingly, it can be ar-
gued that leptin increases bone formation by
enhancing human osteoblast proliferation, colla-
gen synthesis and mineralization.43 Moreover, lep-
tin serves as an osteoblastic antiapoptotic agent by
reducing the mRNA levels of Bax-α/Bcl-2, which
facilitate the transition of mature osteoblasts to os-
teocytes.39,43
Due to the fact that RANKL and OPG are invol-
ved in the interaction between osteoblasts and os-
teoclasts, the influence of leptin upon these mole-
cules was investigated. In an in vitro study, it was
found that leptin decreases RANKL mRNA expres-
sion but had no effect on OPG mRNA levels.23 This
observation raised the hypothesis that leptin can
affect bone remodelling through the RANKL/OPG
pathway. This effect may depend on leptin serum
levels which, in humans, are influenced by food
intake, periods of growth and reproduction.23. 
Conclusions
Cbfa1 and Osx genes are critical in osteoblast dif-
ferentiation. In addition, the Wnt/β-catenin path-
way plays a role not only on osteoblast differenti-
ation but also on its proliferation. In fact, muta-
tions in some of the proteins involved in this path-
way, like LRP5/6 lead to bone diseases. Osteoblasts
are also influenced by leptin in a dual way: inhibi-
tory, through the central nervous system, or sti-
mulatory through the direct binding on surface re-
ceptors. On the other hand, osteoblasts are res-
ponsible for the RANKL/OPG balance which is the
major determinant of osteoclast differentiation. 
Although most of the current therapeutic opti-
ons for osteoporosis antagonize bone resorption,
the increasing knowledge on osteoblast regulation
is creating new hypothetical targets that can trans-
form the future of osteoporosis management.
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